Elekta (EKTAY) Stock Price, News & Analysis

Company Overview

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment. Elekta also provides oncology information systems and treatment planning software that enable seamless integration of imaging, planning and delivery for multidisciplinary clinical teams. In addition, the company offers comprehensive service and support programs, clinical training and educational resources to ensure optimal system performance and professional development for its customers.

Founded in 1972 by Swedish neurosurgeon Lars Leksell, Elekta pioneered stereotactic radiosurgery and has since grown into a worldwide provider of precision cancer care technologies. Headquartered in Stockholm, Sweden, the company serves hospitals, cancer centers and clinics across Europe, North America, Asia-Pacific, Latin America, the Middle East and Africa. Elekta maintains regional offices and service centers to support installation, maintenance and training programs in key markets around the globe.

Guided by a leadership team of experienced executives and a board of directors with deep expertise in healthcare technology, Elekta continues to invest in research and development to advance treatment efficacy and patient quality of life. The company collaborates with academic institutions, clinical partners and industry stakeholders to drive innovation in radiotherapy and radiosurgery and to shape the future of precision cancer care.

Key Stats

• Today's Range: $6.04 to $6.06
• 50-Day Range: $5.66 to $6.69
• 52-Week Range: $4.35 to $6.93
• Volume: 2,955 shs
• Average Volume: 877 shs
• Market Capitalization: $2.23 billion
• P/E Ratio: N/A
• Dividend Yield: 2.15%
• Price Target: N/A
• Consensus Rating: Reduce

Company Calendar

• Last Earnings: 3/05/2026
• Today: 5/08/2026
• Next Earnings (Estimated): 5/27/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EKTAY
• CIK: 1451160
• Web: www.elekta.com
• Phone: (685) 872-5400
• Fax: 46-8-587-255-00
• Employees: 4,556
• Year Founded: 1972

Profitability

• EPS (Trailing Twelve Months): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 15.50
• P/E Growth: N/A
• Net Income: $22.37 million
• Net Margins: -0.08%
• Pretax Margin: 1.10%
• Return on Equity: 12.84%
• Return on Assets: 3.88%

Debt

• Debt-to-Equity Ratio: 0.56
• Current Ratio: 0.95
• Quick Ratio: 0.73

Sales & Book Value

• Annual Sales: $1.71 billion
• Price / Sales: 1.30
• Cash Flow: $0.62 per share
• Price / Cash Flow: 9.75
• Book Value: $2.19 per share
• Price / Book: 2.76

Miscellaneous

• Outstanding Shares: 368,588,000
• Free Float: 216,435,000
• Market Cap: $2.23 billion
• Optionable: Not Optionable
• Beta: 1.01